Reply: Pathophysiological, methodological, and statistical considerations in CGRP monoclonal antibody therapy: A comment on Imai et al
Shungo Imai(Keio University), Tsubasa Takizawa(Keio University), Nobuyuki Takahashi(Keio University Hospital), Jin Nakahara(Keio University Hospital), Satoko Hori(Keio University), Keiko Ihara(Keio University), Chisato Iba(Keio University Hospital), Narumi Watanabe(Keio University Hospital), Seiya Ohtani(Keio University), Ryo Takemura(Keio University Hospital), Kei Ishizuchi(Keio University Hospital)
Cited by 1
Related Papers
Hallmarks of primary headache: part 1 – migraine
|The Journal of Headache and Pain|2024|174
Spreading depolarizations trigger caveolin‐1–dependent endothelial transcytosis
|Annals of Neurology|2018|107
International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine
|Cephalalgia|2024|107
International Headache Society global practice recommendations for the acute pharmacological treatment of migraine
|Cephalalgia|2024|106
Spreading depression as a preclinical model of migraine
|The Journal of Headache and Pain|2019|104